4-Bromobenzo[b]thiophene CAS 5118-13-8 Ucoceko > 97.0% (GC) Brexpiprazole uMvelisi oPhakathi oPhakathi onguMfanekiso

4-Bromobenzo[b]thiophene CAS 5118-13-8 Ucoceko >97.0% (GC) Brexpiprazole Intermediate Manufacturer

Inkcazelo emfutshane:

Igama leKhemikhali: 4-Bromobenzo[b]thiophene

CAS: 5118-13-8

Ubunyulu: >97.0% (GC)

Imbonakalo: Umgubo oqinileyo oMthubi oKhala

Umbindi weBrexpiprazole (CAS: 913611-97-9)

E-Mail: alvin@ruifuchem.com

Thumela i-imeyile kuthi

Iinkcukacha zeMveliso

Iimveliso ezinxulumeneyo

Iithegi zeMveliso

Inkcazo:

Ruifu Chemical Supply Brexpiprazole Intermediates
Brexpiprazole CAS 913611-97-9
7-Hydroxyquinolinone CAS 70500-72-0
4-Bromobenzo[b]thiophene CAS 5118-13-8
1-(1-Benzothiophen-4-yl)piperazine Hydrochloride CAS 913614-18-3
7-(4-Chlorobutoxy)quinolin-2(1H)-enye CAS 913613-82-8
4-Chlorobenzo[b]thiophene CAS 66490-33-3

Iipropati zeMichiza:

Igama leMchiza	4-Bromobenzo[b]thiophene
Izithethantonye	4-Bromobenzothiophene;4-Bromo-Benzo[b]thiophene;4-Bromo-1-Benzothiophene
Inombolo yeCAS	5118-13-8
Inombolo yeCAT	RF-PI1103
Ubume beStokhwe	Kwi-Stock, i-Capacity 30MT / Year
Ifomula yeemolekyuli	C8H5BrS
Ubunzima beMolekyuli	213.09
Uphawu	Ruifu Chemical

Iinkcukacha:

Into	Iinkcukacha
Imbonakalo	Umgubo oMthubi oKhanyayo
Ubunyulu / Indlela yokuHlalutya	>97.0% (GC)
I-Infrared Spectrum	Iyahambelana noLwakhiwo
NMR	Iyahambelana noLwakhiwo
Umgangatho woVavanyo	Umgangatho woShishino
Ukusetyenziswa	Umbindi weBrexpiprazole (CAS: 913611-97-9)

Ukupakishwa kunye noGcino:

Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi

Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma

Izinto eziluncedo:

FAQ:

Isicelo:

I-4-Bromobenzo[b]i-thiophene (i-CAS: 5118-13-8) isetyenziswa njenge-synthetic intermediate eluncedo, kwaye ithunyelwa kakhulu e-Indiya, eMntla Melika, eKorea, eJapan naseYurophu.I-4-Bromobenzo [b] i-thiophene yindawo ephakathi ye-Brexpiprazole (CAS: 913611-97-9).I-Brexpiprazole yavunywa yi-US Food and Drug Administration (FDA) ngoJulayi 10, 2015, kunyango lwe-schizophrenia, kunye nonyango lokuncedisa ukudakumba.I-Brexpiprazole yenzelwe ukubonelela ngokusebenza okuphuculweyo kunye nokunyamezela (umzekelo, i-akathisia encinci, ukungazinzi kunye / okanye ukulala) ngaphezu konyango olumiselweyo lwe-depressive disorder (MDD).I-Brexpiprazole, ethengiswa phantsi kwegama le-brand Rexulti phakathi kwezinye, i-atypical antipsychotic.I-Brexpiprazole yi-dopamine D2 receptor partial agonist kwaye ichazwe njenge "serotonin-dopamine activity modulator" (SDAM).I-Brexpiprazole yaphuhliswa ngu-Otsuka kunye no-Lundbeck, kwaye ithathwa njengendlalifa ye-Otsuka ethengisa kakhulu i-atypical antipsychotic aripiprazole (Abilify).